PDS Biotechnology Corporation (PDSB) Actualités

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

PRINCETON, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS...

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS...

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS...

Form 8-K - Current report

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS...

Form 8-K - Current report

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for...

Form 8-K - Current report

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall...

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech...